Sijin Wen

15.0k total citations · 1 hit paper
302 papers, 10.4k citations indexed

About

Sijin Wen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Sijin Wen has authored 302 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Pulmonary and Respiratory Medicine, 77 papers in Oncology and 43 papers in Cancer Research. Recurrent topics in Sijin Wen's work include Prostate Cancer Treatment and Research (34 papers), Lymphoma Diagnosis and Treatment (20 papers) and Cancer Genomics and Diagnostics (19 papers). Sijin Wen is often cited by papers focused on Prostate Cancer Treatment and Research (34 papers), Lymphoma Diagnosis and Treatment (20 papers) and Cancer Genomics and Diagnostics (19 papers). Sijin Wen collaborates with scholars based in United States, Spain and Greece. Sijin Wen's co-authors include Michael J. Keating, Apostolia M. Tsimberidou, Hagop M. Kantarjian, William G. Wierda, Yu Shen, Razelle Kurzrock, Kim‐Anh Do, Susan Lerner, Christopher J. Logothetis and Susan O’Brien and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Sijin Wen

288 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

2008 508 citations William G. Wierda, Sijin Wen et al. Blood profile →

Peers

Countries citing papers authored by Sijin Wen

Since Specialization

Citations

This map shows the geographic impact of Sijin Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sijin Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sijin Wen more than expected).

Fields of papers citing papers by Sijin Wen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sijin Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sijin Wen. The network helps show where Sijin Wen may publish in the future.

Co-authorship network of co-authors of Sijin Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Sijin Wen. A scholar is included among the top collaborators of Sijin Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sijin Wen. Sijin Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The single-phase computed tomographic angiography clot burden score is independently associated with digital subtraction angiography derived American Society of Interventional and Therapeutic Neuroradiology collateral score 2024 ·British Journal of Radiology ·Dhairya A. Lakhani, Aneri Balar, Manisha Koneru, Sijin Wen, Burak Berksu Ozkara, Richard Wang, Meisam Hoseinyazdi, (unknown), (unknown), Andrew Cho, Kevin Chen, (unknown), Risheng Xu, Victor Urrutia, Gregory W. Albers, Ansaar Rai, Vivek Yedavalli	4
2	A group randomized trial of SCAN! (Skin Cancer Awareness Now!) in Appalachian community pharmacies 2021 ·Research in Social and Administrative Pharmacy ·Kimberly M. Kelly, Virginia Scott, (unknown), Pamela J. Murray, (unknown), (unknown), Sijin Wen, (unknown)	1
3	Risk factors associated with infection of blood-borne virus among people who used methamphetamine 2020 ·BMC Infectious Diseases ·(unknown), Zheng Dai, Sijin Wen, Ruchi Bhandari	25
4	Palliative care for rare advanced lung diseases in underserved Appalachia: Study protocol for a randomized controlled trial 2020 ·Journal of Advanced Nursing ·Ubolrat Piamjariyakul, (unknown), Stephanie Young, Trisha Petitte, Sijin Wen, (unknown), (unknown), (unknown), (unknown), Carol E. Smith	3
5	Processing of Real‐World, Dynamic Natural Stimuli in Autism is Linked to Corticobasal Function 2020 ·Autism Research ·(unknown), Chris Frum, (unknown), Christopher E. Bauer, Sijin Wen, Jad Ramadan, (unknown), James W. Lewis	5
6	Methods of Academic Course Planning for Cancer Biology PhD Students to Enhance Knowledge of Clinical Oncology 2017 ·Cancer Research ·Malcolm D. Mattes, Elizabeth C.S. Swart, (unknown), Sijin Wen, Linda Vona‐Davis	1
7	Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer 2016 ·Molecular Cancer Therapeutics ·Varvara K. Kozyreva, Anna A. Kiseleva, Ryan J. Ice, (unknown), Yuriy V. Loskutov, (unknown), Matthew B. Smolkin, (unknown), Ryan H. Livengood, Mohamad A. Salkeni, Sijin Wen, Hannah Hazard‐Jenkins, (unknown), Callee M. Walsh, (unknown), (unknown), (unknown), Neal Shah, Elena N. Pugacheva	31
8	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses 2014 ·Clinical Cancer Research ·Apostolia M. Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Jankú, Kenneth Aldape, (unknown), Razelle Kurzrock, Donald A. Berry	140
9	CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy 2013 ·Cancer Immunology Research ·Hong Chen, Tihui Fu, Woong‐Kyung Suh, Dimitra Tsavachidou, Sijin Wen, Jianjun Gao, Derek Ng Tang, Qiuming He, Jingjing Sun, Padmanee Sharma	44
10	Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer 2013 ·Clinical Cancer Research ·Ana M. Aparicio, Andrea Harzstark, Paul G. Corn, Sijin Wen, John C. Araujo, Shi‐Ming Tu, Lance C. Pagliaro, Jeri Kim, Randall E. Millikan, Charles J. Ryan, Nizar M. Tannir, Amado J. Zurita, Paul Mathew, Wadih Arap, Patricia Troncoso, Peter F. Thall, Christopher J. Logothetis	311
11	Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy 2013 ·Cancer Immunology Research ·Derek Ng Tang, Yu Shen, Jingjing Sun, Sijin Wen, Jedd D. Wolchok, Jianda Yuan, James P. Allison, Padmanee Sharma	146
12	Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia 2012 ·Journal of Clinical Oncology ·Xavier C. Badoux, Michael J. Keating, Sijin Wen, William G. Wierda, Susan O’Brien, Stefan Faderl, Rachel L. Sargent, Jan A. Burger, Alessandra Ferrajoli	113
13	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative 2012 ·Clinical Cancer Research ·Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra, Ye Yang, Sijin Wen, Donald A. Berry, Razelle Kurzrock	387
14	Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience 2012 ·Clinical Cancer Research ·Jennifer J. Wheler, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Sarina A. Piha‐Paul, Siqing Fu, Stacy L. Moulder, Bettzy Stephen, Sijin Wen, Razelle Kurzrock	77
15	Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience 2011 ·Clinical Cancer Research ·Apostolia M. Tsimberidou, (unknown), Sijin Wen, Jennifer J. Wheler, David S. Hong, Aung Naing, Nancy G. Iskander, (unknown), Razelle Kurzrock	18
16	Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience 2011 ·The Oncologist ·Hazem El‐Osta, David S. Hong, Jennifer J. Wheler, Siqing Fu, Aung Naing, Gerald S. Falchook, Marshall E. Hicks, Sijin Wen, Apostolia M. Tsimberidou, Razelle Kurzrock	53
17	Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience 2009 ·The Journal of Clinical Endocrinology & Metabolism ·Apostolia M. Tsimberidou, Christos Vaklavas, Sijin Wen, David S. Hong, Jennifer J. Wheler, Chaan S. Ng, Aung Naing, (unknown), Naifa L. Busaidy, Maurie Markman, Steven I. Sherman, Razelle Kurzrock	28
18	Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma 2008 ·Clinical Cancer Research ·Jean Hee Kim, Eric Jonasch, Angela Alexander, John D. Short, Shengli Cai, Sijin Wen, Dimitra Tsavachidou, Pheroze Tamboli, Bogdan Czerniak, Kim‐Anh Do, Kevin J. Wu, Laura A. Marlow, Christopher G. Wood, John A. Copland, Cheryl L. Walker	51
19	Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia 2008 ·Blood ·Alessandra Ferrajoli, Bang-Ning Lee, Ellen Schlette, Susan O’Brien, Hui Gao, Sijin Wen, William G. Wierda, Zeev Estrov, Stefan Faderl, Evan N. Cohen, Changping Li, James M. Reuben, Michael J. Keating	304
20	Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma 2006 ·Clinical Cancer Research ·Padmanee Sharma, Yu Shen, Sijin Wen, Dean F. Bajorin, Victor E. Reuter, Lloyd J. Old, Achim A. Jungbluth	75

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact